Cargando…
Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review
Cardiovascular disease is the major cause of mortality worldwide and accounts for approximately 40% of all deaths. Dyslipidemia is one of the primary causes of atherosclerosis and effective interventions to correct dyslipidemia should form an integral component of any strategy aimed at preventing ca...
Autores principales: | Tziomalos, Konstantinos, Athyros, Vasilios G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426786/ https://www.ncbi.nlm.nih.gov/pubmed/17722529 |
Ejemplares similares
-
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013) -
Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
por: Tziomalos, Konstantinos, et al.
Publicado: (2011) -
Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment
por: Athyros, Vasilios G, et al.
Publicado: (2011) -
Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?
por: Athyros, Vasilios G, et al.
Publicado: (2011) -
Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
por: Górniak, Agata, et al.
Publicado: (2023)